Arch Biopartners Inc.
ARCH.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 100.00% | -- | -- | -61.57% | 67.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.00% | -- | -- | -61.57% | 67.73% |
| Cost of Revenue | -135.12% | -76.02% | -95.56% | -41.51% | 120.92% |
| Gross Profit | 118.24% | 109.05% | 78.28% | -88.14% | -200.70% |
| SG&A Expenses | 18.44% | -15.10% | -19.62% | -67.90% | 23.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -73.30% | -53.30% | -85.05% | -63.34% | 139.55% |
| Operating Income | 82.80% | 74.05% | 52.46% | 64.12% | -290.51% |
| Income Before Tax | 75.80% | 72.90% | 48.94% | 48.34% | -544.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 75.80% | 72.90% | 48.94% | 48.34% | -544.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.80% | 72.90% | 48.94% | 48.34% | -544.48% |
| EBIT | 82.80% | 74.05% | 52.46% | 64.12% | -290.51% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 77.44% | 74.76% | 51.47% | 50.00% | -558.62% |
| Normalized Basic EPS | 77.11% | 73.44% | 50.59% | 50.00% | -561.11% |
| EPS Diluted | 77.44% | 74.76% | 51.47% | 50.00% | -558.62% |
| Normalized Diluted EPS | 77.11% | 73.44% | 50.59% | 50.00% | -561.11% |
| Average Basic Shares Outstanding | 7.79% | 5.34% | 4.32% | 3.96% | -2.92% |
| Average Diluted Shares Outstanding | 7.79% | 5.34% | 4.32% | 3.96% | -2.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |